L-α-distearoylphosphatidylcholine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 英文名称: L-α-distearoylphosphatidylcholine
• 英文别名: 1,2-diheptadecanoyl-sn-glycero-3-phosphorylcholine；diheptadecanoylphosphatidylcholine；1,2-diheptadecanoyl-sn-glycero-3-phosphocholine；diheptadecanoyl-sn-glycero-3-phosphocholine；[(2R)-2,3-di(heptadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate
• 化学式: C₄₂H₈₄NO₈P
• 分子量: 762.105
• InChiKey: RTWAYAIMWLNAJW-RRHRGVEJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.5
• 重原子数：
  52
• 可旋转键数：
  42
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  L-α-distearoylphosphatidylcholine 、 beta-胸苷 在 葡萄糖 作用下， 以 氯仿 、 acetate buffer 为溶剂， 反应 2.0h， 以47.4%的产率得到
  参考文献：
  名称：

  Substrate requirements of phospholipase D from Streptomyces netropsis in the transphosphatidylation synthesis of phospolipids

  摘要：

  研究了磷脂底物的结构对网状链霉菌磷脂酶D催化磷脂酰-5′-胸苷产量的影响。反应和产物产率取决于磷脂底物中极性和非极性部分的结构、疏水-亲水平衡以及脂肪酸的不饱和程度。

  DOI：

  10.1007/s10600-006-0030-9

文献信息

• IONIZABLE CATIONIC LIPIDS
  申请人：Akagera Medicines, Inc.

  公开号：US20220162521A1

  公开（公告）日：2022-05-26

  The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.

  本公开提供了可用作离子化阳离子脂质体的化合物。这些离子化阳离子脂质体可用于制备脂质纳米粒子，以将治疗性核酸传递到细胞中。改进了阳离子离子化脂质体的稳定性，以防止在储存过程中发生氧化降解。
• Modulation of release from dry powder formulations
  申请人：Basu K. Sujit

  公开号：US20050003003A1

  公开（公告）日：2005-01-06

  Particles which include a bioactive agent are prepared to have a desired matrix transition temperature. Delivery of the particles via the pulmonary system results in modulation of drug release from the particles. Sustained release and/or sustained pharmacologic action of the drug can be obtained by forming particles which include a combination of phospholipids that are miscible in one another and have a high matrix transition temperature.

  含有生物活性物质的微粒被制备成具有所需的基质转变温度。通过肺系统输送微粒会导致药物从微粒中释放的调节。通过形成包含彼此相溶且具有高基质转变温度的磷脂组合的微粒，可以获得药物的持续释放和/或持续药理作用。
• Polypeptides of pseudomonas aeruginosa
  申请人：ID Biomedical Corporation

  公开号：EP1790659A2

  公开（公告）日：2007-05-30

  The present invention is related to polypeptides, more particularly SPA-1, SPA-2 and SPA-3 polypeptides of Pseudomonas aeruginosa which may be used to prevent, diagnose and/or treat Pseudomonas aeruginosa infection.

  本发明涉及可用于预防、诊断和/或治疗铜绿假单胞菌感染的多肽，尤其是铜绿假单胞菌的 SPA-1、SPA-2 和 SPA-3 多肽。
• Compositions and methods for enhancing contrast in imaging
  申请人：Marval Biosciences, Inc.

  公开号：EP2578237A1

  公开（公告）日：2013-04-10

  Example compositions of liposomes with hydrophilic polymers on their surface, and containing relatively high concentrations of contrast- enhancing agents for computed tomography are provided. Example pharmaceutical compositions of such liposomes, when administered to a subject, provide for increased contrast of extended duration, as measured by computed tomography, in the bloodstream and other tissues of the subject. Also provided are example methods for making liposomes containing high concentrations of contrast-enhancing agents, and example methods for using the compositions.

  本发明提供了一些脂质体组合物实例，这些脂质体表面具有亲水性聚合物，并含有相对高浓度的计算机断层扫描造影剂。这种脂质体的药物组合物范例在给受试者用药时，可使受试者血液和其他组织中的对比度增加，持续时间延长，如计算机断层扫描所测。此外，还提供了制造含有高浓度造影剂的脂质体的示例方法，以及使用这些组合物的示例方法。
• FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND POLYPEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS
  申请人：Children's Hospital Medical Center

  公开号：EP3357490A1

  公开（公告）日：2018-08-08

  The present invention includes pharmaceutical and/or imaging agents and methods for delivering the agent(s) within and/or through the dermal, mucosal and other cellular membranes. The agents can include a fusogenic protein. This technology can be used for applications in which the objective is delivery of active agent within and/or beneath biological membranes and/or across the blood-brain barrier and neuronal membranes.

  本发明包括药物和/或成像制剂以及在皮肤、粘膜和其他细胞膜内和/或通过皮肤、粘膜和其他细胞膜输送制剂的方法。这些制剂可包括致熔蛋白。该技术可用于在生物膜内和/或生物膜下和/或穿过血脑屏障和神经元膜输送活性剂的应用。